Erasca Reports First Quarter 2024 Business Updates and Financial Results
Provided By GlobeNewswire
Last update: May 8, 2024
Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma
Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors
Read more at globenewswire.comNASDAQ:ERAS (8/4/2025, 11:36:49 AM)
1.405
+0.02 (+1.08%)
Find more stocks in the Stock Screener
